Societal CDMO Equity 2024

Societal CDMO Aktienanalyse

What does Societal CDMO do?

Recro Pharma Inc. is a company operating in the biopharmaceutical industry, specializing in the development and marketing of innovative therapeutics. The company is based in Malvern, Pennsylvania, USA, and was founded in 2007. The history of Recro Pharma Inc. dates back to 1985, when the company was founded as ReceptoPharm. In 2008, it was renamed Recro Pharma Inc. to emphasize its focus on pharmaceutical activities. Since then, the company has made significant progress, including successful clinical trials and the introduction of innovative products. Recro Pharma follows a business model based on the development of therapeutics in the areas of pain management and anesthesia. The company aims to create solutions to alleviate pain in patients and improve their quality of life. Recro Pharma's goal is to bring high-quality products to the market that are distinguished by excellent safety, efficacy, and patient tolerance. Recro Pharma's product range currently includes two main areas. Firstly, the company has launched its medication Meloxicam for pain treatment in adults. Secondly, it has developed and distributes a portfolio of anesthesia-related therapeutics through its subsidiary Lumendi LLC. Meloxicam is a non-steroidal anti-inflammatory drug used for pain relief in adults. The medication is available in various forms such as tablets and capsules and is used in both hospital and outpatient care. Lumendi LLC specializes in the development and distribution of anesthesia-related therapeutics. The company's products include those for intubation and muscle relaxation in surgical procedures, as well as anesthesia for pain management. Lumendi's goal is to create innovative solutions to improve medical practice and shorten hospital stays. Recro Pharma Inc. aims to expand its product range through the development of further innovative solutions. The company continues to invest in research and development to develop new products and strengthen its position in the market. In 2020, Recro Pharma Inc. received FDA approval for the product IV Meloxicam. This is an intravenous form of the drug Meloxicam used for pain treatment in adults. This is a significant milestone for the company as it is now able to offer an alternative form of the medication. Recro Pharma Inc. has established itself as a significant player in the biopharmaceutical industry. The company aspires to further strengthen its position in the market and create innovative solutions to improve medical practice. With its high-quality products, Recro Pharma contributes to alleviating patients' pain and improving their quality of life. Societal CDMO ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Societal CDMO's Equity

Societal CDMO's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Societal CDMO's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Societal CDMO's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Societal CDMO's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Societal CDMO’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Societal CDMO stock

What is the equity of Societal CDMO this year?

Societal CDMO has equity of 58.66 M USD this year.

What was the equity of Societal CDMO compared to the previous year?

The equity of Societal CDMO has increased/decreased by -2.07% decreased compared to the previous year.

What impact does a high equity have on investors of Societal CDMO?

A high equity is advantageous for investors of Societal CDMO as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Societal CDMO?

A low equity can be a risk for investors of Societal CDMO, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Societal CDMO affect the company?

An increase in equity of Societal CDMO can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Societal CDMO affect the company?

A reduction in equity of Societal CDMO can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Societal CDMO?

Some factors that can affect the equity of Societal CDMO include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Societal CDMO so important for investors?

The equity of Societal CDMO is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Societal CDMO take to change the equity?

To change equity, Societal CDMO can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Societal CDMO pay?

Over the past 12 months, Societal CDMO paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Societal CDMO is expected to pay a dividend of 0 USD.

What is the dividend yield of Societal CDMO?

The current dividend yield of Societal CDMO is .

When does Societal CDMO pay dividends?

Societal CDMO pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Societal CDMO?

Societal CDMO paid dividends every year for the past 0 years.

What is the dividend of Societal CDMO?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Societal CDMO located?

Societal CDMO is assigned to the 'Health' sector.

Wann musste ich die Aktien von Societal CDMO kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Societal CDMO from 8/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/10/2024.

When did Societal CDMO pay the last dividend?

The last dividend was paid out on 8/10/2024.

What was the dividend of Societal CDMO in the year 2023?

In the year 2023, Societal CDMO distributed 0 USD as dividends.

In which currency does Societal CDMO pay out the dividend?

The dividends of Societal CDMO are distributed in USD.